Cargando…

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes

Anakinra is an interleukin (IL) receptor antagonist that works by blocking the biological activity of IL-1 by competitively inhibiting binding of IL-1 to the type 1 interleukin receptor. IL-1 production is induced in response to inflammatory stimuli and mediates various physiological mechanisms, inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachove, Inessa, Chang, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045113/ https://www.ncbi.nlm.nih.gov/pubmed/27790031 http://dx.doi.org/10.2147/OARRR.S46017

Ejemplares similares

Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra
por: Terrada, Celine, et al.
Publicado: (2011)

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
por: Kullenberg, Torbjörn, et al.
Publicado: (2016)

Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome
por: Dhimolea, Eugen
Publicado: (2011)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Quartier, Pierre
Publicado: (2011)

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
por: Lachmann, Helen J., et al.
Publicado: (2009)

Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response
por: Yu, Justin R., et al.
Publicado: (2010)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
por: Bibalo, C, et al.
Publicado: (2011)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System
por: Keddie, Stephen, et al.
Publicado: (2018)

Neurology of the Cryopyrin-Associated Periodic Feversyndrome
por: Parker, T, et al.
Publicado: (2015)

Erythema nodosum in an adolescent patient with cryopyrin‐associated periodic syndrome
por: Chan, Linda, et al.
Publicado: (2018)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

The First Case Series of Cryopyrin-Associated Periodic Syndrome in Korea
por: Han, Jong Hee, et al.
Publicado: (2019)

Most Important Factors in Diagnosing Cryopyrin-Associated Periodic Syndrome
por: Lee, Soyoung, et al.
Publicado: (2021)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
por: Leinonen, Mika, et al.
Publicado: (2014)

Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Bozkurt, Yasemin, et al.
Publicado: (2015)

Unified modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Gul, A, et al.
Publicado: (2015)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome
por: Kawai, Mariko, et al.
Publicado: (2013)

Cryopyrin‐associated periodic syndrome with inflammatory bowel disease: A case study
por: Raymond, Karen N, et al.
Publicado: (2021)

PReS-FINAL-2234: Successful canakunimab treatment in uveitis secondary to cryopyrin-associated periodic syndrome
por: Kasapcopur, O, et al.
Publicado: (2013)

Interleukine-6 and TNFα blockers provide only partial and short-term temporal improvement in cryopyrin-associated periodic syndrome
por: Dolgikh, Vladimir, et al.
Publicado: (2014)

Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
por: Tilson, Hugh, et al.
Publicado: (2013)

Live‐attenuated vaccines in a cryopyrin‐associated periodic syndrome patient receiving canakinumab treatment during infancy
por: Watanabe, Misa, et al.
Publicado: (2017)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Differences in disease activity in cryopyrin-associated periodic syndrome in mutation-positive and mutation-negative patients
por: Kostik, M, et al.
Publicado: (2015)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

Lessons From the Misdiagnosis of Cryopyrin-Associated Periodic Syndrome as an Infection: Importance of an Early and Precise Diagnosis
por: Li, Tao, et al.
Publicado: (2021)

Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndrome
por: Karasawa, Tadayoshi, et al.
Publicado: (2022)

Cryopyrin-associated Periodic Syndrome in a Family with NLRP3 A441V Mutation
por: SHIRAISHI, Ken, et al.
Publicado: (2022)

Cryopyrin-associated periodic syndromes (CAPS): report on two cases (Muckle-Wells syndrome (MWS) and CINCA/NOMID)
por: Salugina, SO, et al.
Publicado: (2011)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

A Rare Case of Cryopyrin-associated Periodic Syndrome in an Elderly Woman with NLRP3 and MEFV Mutations
por: Nakamichi, Seiko, et al.
Publicado: (2018)

Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome
por: Stackowicz, Julien, et al.
Publicado: (2021)

Necrotizing Funisitis as an Intrauterine manifestation of Cryopyrin-Associated Periodic Syndrome: a case report and review of the literature
por: Yokoi, Kyoko, et al.
Publicado: (2021)

Computational Modeling of NLRP3 Identifies Enhanced ATP Binding and Multimerization in Cryopyrin-Associated Periodic Syndromes
por: Samson, Jenny Mae, et al.
Publicado: (2020)

Late onset of the cryopyrin-associated periodic syndrome (CAPS) associated with low level of somatic mosaicism in six patients
por: Rowczenio, D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8lovb8jrgi9sisr7jmqkussoa2